Choose from nearly 1,000 secondary antibodies conjugated to more than 40 different enzymatic, fluorescent, or biotin labels. Use the filters on the left to sort our secondary antibodies by species, application, host, or conjugate.
To learn more about secondary antibodies, download and read our Secondary Antibody Handbook for technical information and tips to guide you when choosing a secondary antibody for your experiment.
To understand more about direct vs. indirect detection, including benefits of a secondary antibody and when to use one, please read our resources on Direct vs. Indirect Detection Methods.
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Alkaline Phosphatase | NB7447 | |||
| Allophycocyanin | NB7446APC | |||
| Biotin | NB7446B | |||
| DyLight 350 | NB7446UV | |||
| DyLight 405 | NB7446V | |||
| DyLight 488 | NB7446G | |||
| DyLight 550 | NB7446R | |||
| DyLight 594 | NB7446DL594 | |||
| DyLight 650 | NB7446C | |||
| DyLight 680 | NB7446FR | |||
| DyLight 755 | NB7446IR | |||
| FITC | NB7448 | |||
| HRP | NB7449 | |||
| PE | NB7446PE | |||
| PerCP | NB7446PCP | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Alkaline Phosphatase | NB7464 | |||
| Allophycocyanin | NB7463APC | |||
| Biotin | NB7463B | |||
| DyLight 350 | NB7463UV | |||
| DyLight 405 | NB7463V | |||
| DyLight 488 | NB7463G | |||
| DyLight 550 | NB7463R | |||
| DyLight 594 | NB7463DL594 | |||
| DyLight 650 | NB7463C | |||
| DyLight 680 | NB7463FR | |||
| DyLight 755 | NB7463IR | |||
| FITC | NB7465 | |||
| HRP | NB7466 | |||
| PE | NB7463PE | |||
| PerCP | NB7463PCP | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Alkaline Phosphatase | NBP1-74975 | |||
| Biotin | NBP1-74976 | |||
| DyLight 488 | NBP1-74980 | |||
| DyLight 550 | NBP1-75816 | |||
| DyLight 594 | NBP1-75817 | |||
| DyLight 633 | NBP1-75818 | |||
| FITC | NBP1-74977 | |||
| HRP | NBP1-74978 | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Allophycocyanin | NB7487APC | |||
| Biotin | NB7487B | |||
| DyLight 350 | NB7487UV | |||
| DyLight 405 | NB7487V | |||
| DyLight 488 | NB7487G | |||
| DyLight 550 | NB7487R | |||
| DyLight 594 | NB7487DL594 | |||
| DyLight 650 | NB7487C | |||
| DyLight 680 | NB7487FR | |||
| DyLight 755 | NB7487IR | |||
| FITC | NB7488 | |||
| HRP | NB7489 | |||
| PE | NB7487PE | |||
| PerCP | NB7487PCP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Pre-adsorbed | NB7488 | |||
| Pre-adsorbed | NB7489 | |||
| Pre-adsorbed | NB7487B | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Alkaline Phosphatase | NB7476 | |||
| Allophycocyanin | NB7475APC | |||
| Biotin | NB7475B | |||
| DyLight 350 | NB7475UV | |||
| DyLight 405 | NB7475V | |||
| DyLight 488 | NB7475G | |||
| DyLight 550 | NB7475R | |||
| DyLight 594 | NB7475DL594 | |||
| DyLight 650 | NB7475C | |||
| DyLight 680 | NB7475FR | |||
| DyLight 755 | NB7475IR | |||
| FITC | NB7477 | |||
| PE | NB7475PE | |||
| PerCP | NB7475PCP | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Alkaline Phosphatase | NBP1-75025 | |||
| Biotin | NBP1-75026 | |||
| FITC | NBP1-75027 | |||
| HRP | NBP1-75028 | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Alkaline Phosphatase | NBP1-74910 | |||
| Biotin | NBP1-74911 | |||
| DyLight 550 | NBP1-75759 | |||
| DyLight 650 | NBP1-75762 | |||
| DyLight 800 | NBP1-75764 | |||
| FITC | NBP1-74912 | |||
| HRP | NBP1-74913 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Pre-adsorbed | NBP1-74910 | |||
| Pre-adsorbed | NBP1-74911 | |||
| Pre-adsorbed | NBP1-74912 | |||
| Pre-adsorbed | NBP1-74913 | |||
| Pre-adsorbed | NBP1-75759 | |||
| Pre-adsorbed | NBP1-75762 | |||
| Pre-adsorbed | NBP1-75764 | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Alkaline Phosphatase | NBP1-75032 | |||
| Biotin | NBP1-75033 | |||
| FITC | NBP1-75034 | |||
| HRP | NBP1-75035 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Pre-adsorbed | NBP1-75032 | |||
| Pre-adsorbed | NBP1-75033 | |||
| Pre-adsorbed | NBP1-75034 | |||
| Pre-adsorbed | NBP1-75035 | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Biotin | NBP1-74955 | |||
| FITC | NBP1-74956 | |||
| HRP | NBP1-74957 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Pre-adsorbed | NBP1-74955 | |||
| Pre-adsorbed | NBP1-74956 | |||
| Pre-adsorbed | NBP1-74957 | |||
![Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - A) Kidney from control did not show any specific staining in the glomeruli. Only erythrocytes (arrow) showed weak fluorescence. B) 1 day: endothelium & material within the capillaries of a glomerulus were highly fluorescent (white arrow). In an adjacent glomerulus, only the endothelium was stained (white arrowhead) not for the lumina of the vessels (black arrow). C) Erythrocytes (arrowhead) and endothelium (arrow). D) 7 days: fluorescence within the capillaries (arrowhead) & endothelium was weaker. E) 1 day after ranibizumab injection, the endothelium cell layer (white arrow) and erythrocytes (arrowhead and black arrow) were fluorescent. F) The fluorescence (arrowhead) was nearly lost 7 days after injection. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0113701) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Goat-anti-Human-IgG-Fc-fragment-Secondary-Antibody-Immunohistochemistry-NB7446-img0002.jpg "Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - A) Kidney from control did not show any specific staining in the glomeruli. Only erythrocytes (arrow) showed weak fluorescence. B) 1 day: endothelium & material within the capillaries of a glomerulus were highly fluorescent (white arrow). In an adjacent glomerulus, only the endothelium was stained (white arrowhead) not for the lumina of the vessels (black arrow). C) Erythrocytes (arrowhead) and endothelium (arrow). D) 7 days: fluorescence within the capillaries (arrowhead) & endothelium was weaker. E) 1 day after ranibizumab injection, the endothelium cell layer (white arrow) and erythrocytes (arrowhead and black arrow) were fluorescent. F) The fluorescence (arrowhead) was nearly lost 7 days after injection. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0113701) licensed under a CC-BY license.")
![Western Blot: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Image from verified customer review. Image using the HRP form of this antibody.](http://images.novusbio.com/fullsize/Goat-anti-Human-IgG-Fc-Secondary-Antibody-Western-Blot-NB7446-img0001.jpg)
![Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Immune fluorescent photomicrographs of glomeruli from control (A), aflibercept-treated (B–D) & ranibizumab-treated (E–F) monkeys eyes.In all figures, the asterisks label the spaces of the Bowman capsule. A) Kidney sections from the control animal did not show any specific staining with anti-human IgG-Fc antibody in the glomeruli. Only the erythrocytes (arrow) within the capillaries showed a weak fluorescence. B) One day after aflibercept injection, the endothelium cell layer & material within the capillaries of a glomerulus were highly fluorescent (white arrow) after labelling with an antibody against the Fc region of IgG. In an adjacent glomerulus, only the endothelium was stained (white arrowhead) whereas the lumina of the vessels did not contain IgG-Fc positive material (black arrow). C) Erythrocytes within the glomeruli (arrowhead) as well as the endothelium (arrow) were highly fluorescent. D) Seven days after aflibercept injection, the fluorescent material within the capillaries (arrowhead) & the fluorescence intensity of the endothelium became weaker. E) One day after ranibizumab injection, the endothelium cell layer (white arrow) & erythrocytes (arrowhead & black arrow in the inset) were fluorescent after staining with an antibody against human Fab of IgG. F) The specific fluorescence of the endothelium (arrow) & erythrocytes (arrowhead) was nearly lost seven days after injection of ranibizumab. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25415380), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb7446_goat-polyclonal-goat-anti-human-igg-fc-secondary-antibody-310202416154644.jpg)
![Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Immune fluorescent photomicrographs of glomeruli from control (A), aflibercept-treated (B–D) & ranibizumab-treated (E–F) monkeys eyes.In all figures, the asterisks label the spaces of the Bowman capsule. A) Kidney sections from the control animal did not show any specific staining with anti-human IgG-Fc antibody in the glomeruli. Only the erythrocytes (arrow) within the capillaries showed a weak fluorescence. B) One day after aflibercept injection, the endothelium cell layer & material within the capillaries of a glomerulus were highly fluorescent (white arrow) after labelling with an antibody against the Fc region of IgG. In an adjacent glomerulus, only the endothelium was stained (white arrowhead) whereas the lumina of the vessels did not contain IgG-Fc positive material (black arrow). C) Erythrocytes within the glomeruli (arrowhead) as well as the endothelium (arrow) were highly fluorescent. D) Seven days after aflibercept injection, the fluorescent material within the capillaries (arrowhead) & the fluorescence intensity of the endothelium became weaker. E) One day after ranibizumab injection, the endothelium cell layer (white arrow) & erythrocytes (arrowhead & black arrow in the inset) were fluorescent after staining with an antibody against human Fab of IgG. F) The specific fluorescence of the endothelium (arrow) & erythrocytes (arrowhead) was nearly lost seven days after injection of ranibizumab. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25415380), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb7446_goat-polyclonal-goat-anti-human-igg-fc-secondary-antibody-310202416165644.jpg)
![Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Immune fluorescent photomicrographs of glomeruli from control (A), aflibercept-treated (B–D) & ranibizumab-treated (E–F) monkeys eyes.In all figures, the asterisks label the spaces of the Bowman capsule. A) Kidney sections from the control animal did not show any specific staining with anti-human IgG-Fc antibody in the glomeruli. Only the erythrocytes (arrow) within the capillaries showed a weak fluorescence. B) One day after aflibercept injection, the endothelium cell layer & material within the capillaries of a glomerulus were highly fluorescent (white arrow) after labelling with an antibody against the Fc region of IgG. In an adjacent glomerulus, only the endothelium was stained (white arrowhead) whereas the lumina of the vessels did not contain IgG-Fc positive material (black arrow). C) Erythrocytes within the glomeruli (arrowhead) as well as the endothelium (arrow) were highly fluorescent. D) Seven days after aflibercept injection, the fluorescent material within the capillaries (arrowhead) & the fluorescence intensity of the endothelium became weaker. E) One day after ranibizumab injection, the endothelium cell layer (white arrow) & erythrocytes (arrowhead & black arrow in the inset) were fluorescent after staining with an antibody against human Fab of IgG. F) The specific fluorescence of the endothelium (arrow) & erythrocytes (arrowhead) was nearly lost seven days after injection of ranibizumab. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25415380), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb7446_goat-polyclonal-goat-anti-human-igg-fc-secondary-antibody-310202416154630.jpg)
![Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Immune fluorescent photomicrographs of glomeruli from control (A), aflibercept-treated (B–D) & ranibizumab-treated (E–F) monkeys eyes.In all figures, the asterisks label the spaces of the Bowman capsule. A) Kidney sections from the control animal did not show any specific staining with anti-human IgG-Fc antibody in the glomeruli. Only the erythrocytes (arrow) within the capillaries showed a weak fluorescence. B) One day after aflibercept injection, the endothelium cell layer & material within the capillaries of a glomerulus were highly fluorescent (white arrow) after labelling with an antibody against the Fc region of IgG. In an adjacent glomerulus, only the endothelium was stained (white arrowhead) whereas the lumina of the vessels did not contain IgG-Fc positive material (black arrow). C) Erythrocytes within the glomeruli (arrowhead) as well as the endothelium (arrow) were highly fluorescent. D) Seven days after aflibercept injection, the fluorescent material within the capillaries (arrowhead) & the fluorescence intensity of the endothelium became weaker. E) One day after ranibizumab injection, the endothelium cell layer (white arrow) & erythrocytes (arrowhead & black arrow in the inset) were fluorescent after staining with an antibody against human Fab of IgG. F) The specific fluorescence of the endothelium (arrow) & erythrocytes (arrowhead) was nearly lost seven days after injection of ranibizumab. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25415380), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb7446_goat-polyclonal-goat-anti-human-igg-fc-secondary-antibody-310202416175295.jpg)
![Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Immune fluorescent photomicrographs of glomeruli from control (A), aflibercept-treated (B–D) & ranibizumab-treated (E–F) monkeys eyes.In all figures, the asterisks label the spaces of the Bowman capsule. A) Kidney sections from the control animal did not show any specific staining with anti-human IgG-Fc antibody in the glomeruli. Only the erythrocytes (arrow) within the capillaries showed a weak fluorescence. B) One day after aflibercept injection, the endothelium cell layer & material within the capillaries of a glomerulus were highly fluorescent (white arrow) after labelling with an antibody against the Fc region of IgG. In an adjacent glomerulus, only the endothelium was stained (white arrowhead) whereas the lumina of the vessels did not contain IgG-Fc positive material (black arrow). C) Erythrocytes within the glomeruli (arrowhead) as well as the endothelium (arrow) were highly fluorescent. D) Seven days after aflibercept injection, the fluorescent material within the capillaries (arrowhead) & the fluorescence intensity of the endothelium became weaker. E) One day after ranibizumab injection, the endothelium cell layer (white arrow) & erythrocytes (arrowhead & black arrow in the inset) were fluorescent after staining with an antibody against human Fab of IgG. F) The specific fluorescence of the endothelium (arrow) & erythrocytes (arrowhead) was nearly lost seven days after injection of ranibizumab. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25415380), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb7446_goat-polyclonal-goat-anti-human-igg-fc-secondary-antibody-310202416163732.jpg)
![Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Immune fluorescent photomicrographs of glomeruli from control (A), aflibercept-treated (B–D) & ranibizumab-treated (E–F) monkeys eyes.In all figures, the asterisks label the spaces of the Bowman capsule. A) Kidney sections from the control animal did not show any specific staining with anti-human IgG-Fc antibody in the glomeruli. Only the erythrocytes (arrow) within the capillaries showed a weak fluorescence. B) One day after aflibercept injection, the endothelium cell layer & material within the capillaries of a glomerulus were highly fluorescent (white arrow) after labelling with an antibody against the Fc region of IgG. In an adjacent glomerulus, only the endothelium was stained (white arrowhead) whereas the lumina of the vessels did not contain IgG-Fc positive material (black arrow). C) Erythrocytes within the glomeruli (arrowhead) as well as the endothelium (arrow) were highly fluorescent. D) Seven days after aflibercept injection, the fluorescent material within the capillaries (arrowhead) & the fluorescence intensity of the endothelium became weaker. E) One day after ranibizumab injection, the endothelium cell layer (white arrow) & erythrocytes (arrowhead & black arrow in the inset) were fluorescent after staining with an antibody against human Fab of IgG. F) The specific fluorescence of the endothelium (arrow) & erythrocytes (arrowhead) was nearly lost seven days after injection of ranibizumab. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25415380), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb7446_goat-polyclonal-goat-anti-human-igg-fc-secondary-antibody-310202416171447.jpg)
![Immunocytochemistry/Immunofluorescence: Goat anti-Human Kappa Light Chain Secondary Antibody [NB7463] - JJN3 and 8226 Human myeloma cells stained with NB7463. Cells fixed in 4%PFA 10min, wash PBS X 3. Permeabilized 0.5% Triton X-100 5min; wash PBS X 3. Block 10% donkey serum 1hr. 1:10,000 NB7463 O/N at 4C; wash PBS X 3 and 1:2000 donkey F(ab')2 Alexa Fluor Cy3 anti-goat IgG (H+L) 1 hour at room temp; wash PBS X 3. Olympus/BIOVIEW Cy3 filter 300ms exposure. Image form verified customer review.](http://images.novusbio.com/fullsize/Goat-anti-Human-Kappa-Light-Chain-Secondary-Antibody-Immunocytochemistry-Immunofluorescence-NB7463-img0001.jpg "Immunocytochemistry/Immunofluorescence: Goat anti-Human Kappa Light Chain Secondary Antibody [NB7463] - JJN3 and 8226 Human myeloma cells stained with NB7463. Cells fixed in 4%PFA 10min, wash PBS X 3. Permeabilized 0.5% Triton X-100 5min; wash PBS X 3. Block 10% donkey serum 1hr. 1:10,000 NB7463 O/N at 4C; wash PBS X 3 and 1:2000 donkey F(ab')2 Alexa Fluor Cy3 anti-goat IgG (H+L) 1 hour at room temp; wash PBS X 3. Olympus/BIOVIEW Cy3 filter 300ms exposure. Image form verified customer review.")
![Immunocytochemistry/Immunofluorescence: Goat anti-Human IgG Fc Secondary Antibody [NBP1-74974] - SKBR3 human breast cancer cell line. Image from verified customer review. Analysis using the DyLight-550 conjugated antibody.](http://images.novusbio.com/fullsize/Goat-anti-Human-IgG-Fc-fragment-Secondary-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-74974-img0003.jpg "Immunocytochemistry/Immunofluorescence: Goat anti-Human IgG Fc Secondary Antibody [NBP1-74974] - SKBR3 human breast cancer cell line. Image from verified customer review. Analysis using the DyLight-550 conjugated antibody.")
![Immunocytochemistry/Immunofluorescence: Goat anti-Human IgG Fc Secondary Antibody [NBP1-74974] - MCF7 human breast cancer cell line. Image from verified customer review.](http://images.novusbio.com/fullsize/Goat-anti-Human-IgG-Fc-fragment-Secondary-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-74974-img0001.jpg)
![Immunocytochemistry/Immunofluorescence: Goat anti-Human IgG Fc Secondary Antibody [NBP1-74974] - SKBR3 human breast cancer cell line. Image from verified customer review.](http://images.novusbio.com/fullsize/Goat-anti-Human-IgG-Fc-fragment-Secondary-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-74974-img0002.jpg)
![Immunocytochemistry/Immunofluorescence: Goat anti-Human IgG (H+L) Secondary Antibody [NB7475] - This Goat anti-Human IgG (H+L) Secondary Antibody conjugated with pHAb Dyes which have excitation maxima (Ex ) at 532nm and emission maxima (Em) at 560nm. Used this with primary antibody of interest to visualize cells and study Internalisation using microscope. This image was submitted via customer review.](http://images.novusbio.com/fullsize/Goat-anti-Human-IgG-H+L-Secondary-Antibody-Immunocytochemistry-Immunofluorescence-NB7475-img0005.jpg "Immunocytochemistry/Immunofluorescence: Goat anti-Human IgG (H+L) Secondary Antibody [NB7475] - This Goat anti-Human IgG (H+L) Secondary Antibody conjugated with pHAb Dyes which have excitation maxima (Ex ) at 532nm and emission maxima (Em) at 560nm. Used this with primary antibody of interest to visualize cells and study Internalisation using microscope. This image was submitted via customer review.")
![Immunocytochemistry/Immunofluorescence: Goat anti-Human IgG (H+L) Secondary Antibody [NB7475] - Human SKCO1 cells. Image from verified customer review. Image using the FITC form of Goat anti-Human IgG (H+L) Secondary Antibody.](http://images.novusbio.com/fullsize/Goat-anti-Human-IgG-H+L-Secondary-Antibody-Immunocytochemistry-Immunofluorescence-NB7475-img0006.jpg)
![Western Blot: Goat anti-Human Lambda Light Chain Secondary Antibody [Unconjugated] [NBP1-72788] - Lane 1: Human lambda (lambda chain). Lane 2: None. Load: 100 ng per lane. Primary antibody: Human lambda (lambda chain) Antibody at 1:1000 for overnight at 4C. Secondary antibody: DyLight800 Donkey anti-Goat at 1:20,000 for 30 min at RT. Block: incubated with blocking buffer for 30 min at RT. Other Band(s): None.](http://images.novusbio.com/fullsize/Goat-anti-Human-Lambda-Light-Chain-Secondary-Antibody-Western-Blot-NBP1-72788-img0005.jpg "Western Blot: Goat anti-Human Lambda Light Chain Secondary Antibody [Unconjugated] [NBP1-72788] - Lane 1: Human lambda (lambda chain). Lane 2: None. Load: 100 ng per lane. Primary antibody: Human lambda (lambda chain) Antibody at 1:1000 for overnight at 4C. Secondary antibody: DyLight800 Donkey anti-Goat at 1:20,000 for 30 min at RT. Block: incubated with blocking buffer for 30 min at RT. Other Band(s): None.")
![Immunocytochemistry/Immunofluorescence: Goat anti-Human Lambda Light Chain Secondary Antibody [Unconjugated] [NBP1-72788] - Human multiple myeloma cell lines 8226, LP-1, H929. 1. Cells immersion-fixed in 4% PFA for 10 minutes, washed 3x with PBS. Permeabilized with 0.5% Triton X-100 for 5 minutes, washed 3x with PBS. Blocked with 10% donkey serum 1 hour. NBP1-72788 antibody at 1:5000 O/N at 4C, washed 3x with PBS. Secondary antibody at 1:2000 donkey F(ab')Cy3 anti-goat IgG (H+L) 1 hour at room temp (Jackson #705-166-147); washed 3x with PBS. Imaging with Olympus/BIOVIEW Cy3 filter 300ms exposure. ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/Goat-anti-Human-Lambda-Light-Chain-Secondary-Antibody-[Unconjugated]-Immunocytochemistry-Immunofluorescence-NBP1-72788-img0006.jpg)
![Immunocytochemistry/Immunofluorescence: Goat anti-Human IgG (H+L) Secondary Antibody (Pre-adsorbed) [NBP1-74953] - Goat anti-Human IgG (H+L) Secondary Antibody (Pre-adsorbed) gives very strong signal with low background when staining live cells (human cancer cell line) with humanized primary antibody. Image from verified customer review. Image using the FITC format of this antibody.](http://images.novusbio.com/fullsize/Goat-anti-Human-IgG-H+L-Secondary-Antibody-Pre-adsorbed-Immunocytochemistry-Immunofluorescence-NBP1-74953-img0002.jpg "Immunocytochemistry/Immunofluorescence: Goat anti-Human IgG (H+L) Secondary Antibody (Pre-adsorbed) [NBP1-74953] - Goat anti-Human IgG (H+L) Secondary Antibody (Pre-adsorbed) gives very strong signal with low background when staining live cells (human cancer cell line) with humanized primary antibody. Image from verified customer review. Image using the FITC format of this antibody.")